Elizabeth Kelly

Elizabeth Kelly

Elizabeth joined Pappas Capital in 2021. Prior to joining Pappas, she consulted for early-stage life sciences and technology companies, coaching, and advising management teams on fundraising, growth, competitive and business development strategies. Elizabeth was previously part of the investment team at Echo Health Ventures, and its predecessor, Mosaic Health Solutions, both subsidiaries of Blue Cross NC. She worked on all aspects of the investment process, from identifying and evaluating digital health investment opportunities, to closing transactions and working with portfolio companies to accelerate growth strategies. Elizabeth structured the merger of Mosaic and Cambia Health Solutions’ investment teams that resulted in the launch of Echo in 2016. In addition, she took on an interim role advising Blue Cross NC on corporate development initiatives, contributing financial and operational expertise to set-up a payer-provider joint venture. Prior to Mosaic, Elizabeth had a variety of cross-functional responsibilities at Chimerix (NASDAQ: CMRX), a biopharmaceutical company developing antiviral therapies. In addition to playing a leadership role in the company’s 2013 IPO, she spearheaded activities in corporate development, finance, marketing, IR, and PR. She began her career as an Analyst at Pappas Ventures, where she managed the deal flow process and supported fundraising efforts for a $102 million new venture fund.


University of North Carolina at Chapel Hill – Kenan-Flagler Business School (MBA in Finance, Entrepreneurship)
University of North Carolina at Chapel Hill (BA in Management, Spanish)

Bert Kinsey, PhD, PharmD

Bert joined Pappas Capital in 2020 and brings significant experience in translational biomedical research and biotechnology equity research. Prior to joining Pappas, he spent two years at RBC Capital Markets in New York City as a Senior Associate on an Institutional Investor-ranked equity research team covering large-, mid- and small-cap biotechnology companies. At RBC he gained experience building and maintaining financial models, vetting public and private biotechnology companies to support investment banking, and conducted clinical and commercial diligence to shape investment theses. Prior to RBC, Bert was Associate Professor of Medicine at the University of Virginia (UVA) where he established an independent research laboratory investigating the role of the immune system in different forms of kidney disease. Throughout his 10 years at UVA, his laboratory was consistently funded by the NIH, including R01, R21, K01 and F32 grants focused on the role of regulatory T cells in acute kidney injury. His academic experience included in vitro and in vivo preclinical experimentation, as well as translational clinical research in cardiac surgery patients.

Bert currently serves as an observer for Ribometrix and previously served as an observer for Reneo Pharmaceuticals.


Medical University of South Carolina (PhD in Pharmaceutical and Biomedical Sciences)
Medical University of South Carolina (Doctor of Pharmacy/PharmD)


Featured Image

Cookie Yu, PhD

Cookie comes from a multidisciplinary scientific background and is actively involved in evaluating investment opportunities for Pappas Capital. Prior to joining Pappas in 2019, she worked as an analyst at M. Ventures, a subsidiary of Merck KGaA, in Darmstadt, Germany. During her time at M. Ventures, Cookie performed market analysis in a wide range of life science and therapeutic areas for venture opportunities, in alignment with global corporate strategies. She also served on the financial team and received training in venture fund controlling.

Before becoming a venture capitalist, Cookie was a researcher at Stony Brook University, where she developed platform technologies in cardiac optogenetics and single cell analysis. In 2016, Cookie was selected as a recipient of the Program for Excellence in Science Award from AAAS. During her time at Stony Brook, Cookie also worked with the New York State Center for Biotechnology on assessing the commercial potential of discovery-stage programs and formulating their development and financing strategies. She supplemented her life science technical expertise with financial understanding by passing the CFA Level I exam. When she is not scouting new technologies, Cookie enjoys foraging wild mushrooms in the forests, traveling, and Latin dancing.

Cookie currently serves as a director for Allievex and as an observer for CuraSen.


Stony Brook University  (PhD in Biomedical Engineering)